Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systematic and combined endosonographic staging of lung cancer (SCORE study).
Crombag LMM, Dooms C, Stigt JA, Tournoy KG, Schuurbiers OCJ, Ninaber MK, Buikhuisen WA, Hashemi SMS, Bonta PI, Korevaar DA, Annema JT. Crombag LMM, et al. Among authors: hashemi sms. Eur Respir J. 2019 Feb 7;53(2):1800800. doi: 10.1183/13993003.00800-2018. Print 2019 Feb. Eur Respir J. 2019. PMID: 30578389 Free article.
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
Thunnissen E, Lissenberg-Witte BI, van den Heuvel MM, Monkhorst K, Skov BG, Sørensen JB, Mellemgaard A, Dingemans AMC, Speel EJM, de Langen AJ, Hashemi SMS, Bahce I, van der Drift MA, Looijen-Salamon MG, Gosney J, Postmus PE, Samii SMS, Duplaquet F, Weynand B, Durando X, Penault-Llorca F, Finn S, Grady AO, Oz B, Akyurek N, Buettner R, Wolf J, Bubendorf L, Duin S, Marondel I, Heukamp LC, Timens W, Schuuring EMD, Pauwels P, Smit EF. Thunnissen E, et al. Among authors: hashemi sms. Lung Cancer. 2019 Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023. Epub 2019 Oct 3. Lung Cancer. 2019. PMID: 31630043
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C, Senan S, Schneiders FL, Veltman J, Hashemi S, Daniels JMA, Fransen M, Heineman DJ, Radonic T, van de Ven PM, Bartelink IH, Meijboom LJ, Garcia-Vallejo JJ, Oprea-Lager DE, de Gruijl TD, Bahce I. Dickhoff C, et al. BMC Cancer. 2020 Aug 14;20(1):764. doi: 10.1186/s12885-020-07263-9. BMC Cancer. 2020. PMID: 32795284 Free PMC article.
Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer.
Ronden MI, Bahce I, Hashemi SMS, Dickhoff C, de Haan PF, Becker A, Spoelstra FOB, Dahele MR, Ali R, Tiemessen MA, Tarasevych S, Maassen van den Brink K, Haasbeek CJA, Daniels JMA, van Laren M, Verbakel WFAR, Senan S. Ronden MI, et al. Among authors: hashemi sms. Lung Cancer. 2021 Feb;152:149-156. doi: 10.1016/j.lungcan.2020.12.019. Epub 2020 Dec 24. Lung Cancer. 2021. PMID: 33418430
Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
Hashemi S, Fransen MF, Niemeijer A, Ben Taleb N, Houda I, Veltman J, Becker-Commissaris A, Daniels H, Crombag L, Radonic T, Jongeneel G, Tarasevych S, Looysen E, van Laren M, Tiemessen M, van Diepen V, Maassen-van den Brink K, Thunnissen E, Bahce I. Hashemi S, et al. Lung Cancer. 2021 Mar;153:81-89. doi: 10.1016/j.lungcan.2021.01.013. Epub 2021 Jan 14. Lung Cancer. 2021. PMID: 33465698 Free article.
44 results